160 related articles for article (PubMed ID: 35594161)
1. Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy.
Nasser-Ghodsi N; Mara K; Allen AM; Watt KD
Clin Transplant; 2022 Aug; 36(8):e14714. PubMed ID: 35594161
[TBL] [Abstract][Full Text] [Related]
2. De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations.
Nasser-Ghodsi N; Mara K; Watt KD
Hepatology; 2021 Aug; 74(2):1003-1013. PubMed ID: 33544906
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
[TBL] [Abstract][Full Text] [Related]
4. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.
Stepanova M; Henry L; Garg R; Kalwaney S; Saab S; Younossi Z
BMC Gastroenterol; 2015 Dec; 15():175. PubMed ID: 26666336
[TBL] [Abstract][Full Text] [Related]
5. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
Bhat M; Mara K; Dierkhising R; Watt KD
Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Steatohepatitis After Liver Transplantation.
Cotter TG; Charlton M
Liver Transpl; 2020 Jan; 26(1):141-159. PubMed ID: 31610081
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting.
Balitzer D; Tsai JH; Gill RM
Diagn Pathol; 2022 Aug; 17(1):65. PubMed ID: 35948927
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.
Younossi ZM; Stepanova M; Ong J; Trimble G; AlQahtani S; Younossi I; Ahmed A; Racila A; Henry L
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):580-589.e5. PubMed ID: 32531342
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients.
Losurdo G; Castellaneta A; Rendina M; Carparelli S; Leandro G; Di Leo A
Aliment Pharmacol Ther; 2018 Mar; 47(6):704-714. PubMed ID: 29359341
[TBL] [Abstract][Full Text] [Related]
11. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.
Kappus M; Abdelmalek M
Clin Liver Dis; 2017 May; 21(2):321-335. PubMed ID: 28364816
[TBL] [Abstract][Full Text] [Related]
12. De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients.
Gitto S; de Maria N; di Benedetto F; Tarantino G; Serra V; Maroni L; Cescon M; Pinna AD; Schepis F; Andreone P; Villa E
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):766-773. PubMed ID: 29505475
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends of De Novo Malignancy Development After Heart Transplantation.
Youn JC; Stehlik J; Wilk AR; Cherikh W; Kim IC; Park GH; Lund LH; Eisen HJ; Kim DY; Lee SK; Choi SW; Han S; Ryu KH; Kang SM; Kobashigawa JA
J Am Coll Cardiol; 2018 Jan; 71(1):40-49. PubMed ID: 29301626
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
[TBL] [Abstract][Full Text] [Related]
15. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.
VanWagner LB; Lapin B; Skaro AI; Lloyd-Jones DM; Rinella ME
Liver Int; 2015 Dec; 35(12):2575-83. PubMed ID: 25977117
[TBL] [Abstract][Full Text] [Related]
16. Long-term probability of and mortality from de novo malignancy after liver transplantation.
Watt KD; Pedersen RA; Kremers WK; Heimbach JK; Sanchez W; Gores GJ
Gastroenterology; 2009 Dec; 137(6):2010-7. PubMed ID: 19766646
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
[TBL] [Abstract][Full Text] [Related]
18. Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis.
Agbim U; Jiang Y; Kedia SK; Singal AK; Ahmed A; Bhamidimarri KR; Bernstein DE; Harrison SA; Younossi ZM; Satapathy SK
Liver Transpl; 2019 Jan; 25(1):68-78. PubMed ID: 30091296
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.
Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD
Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287
[TBL] [Abstract][Full Text] [Related]
20. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
